Shots:
- Mosaic has in-licensed ASTX029 & ASTX295 from Astex (Otsuka Pharmaceutical’s subsidiary) to develop combination therapies using these assets, with the 1st combination study expected to begin in 2026
- As per the deal, Astex granted Mosaic exclusive rights to develop combination products for pts with limited therapy options, receiving a 19% equity stake upfront & additional 3% based on clinical milestones along with potential future revenue shares; other financial terms remain undisclosed
- ASTX029 (ERK1/2 inhibitor), discovered by Astex & evaluated in a P-II trial, while ASTX295 (MDM2 antagonist) developed with Cancer Research UK’s Drug Discovery Unit at Newcastle University & was assessed in a P-I trial, both showing favorable safety in >100 pts each
Ref: Businesswire | Image: Mosaic Therapeutics & Astex Pharmaceutical
Related News:- Repertoire Immune Medicines Collaborates with Genentech to Develop T cell-Targeted Therapies for an Autoimmune Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
